Introduction {#s1}
============

The N-acyl amino acids are a large family of bioactive lipids composed of a fatty-acid tail conjugated to an amino acid head group. Structurally, N-acyl amino acids are closely related to the other bioactive fatty acid amides including the endogenous cannabinoid receptor agonist anandamide (N-arachidonoylethanolamine) and the N-acyl-homoserine lactone family of bacterial quorum-sensing molecules ([@bib14]; [@bib32]). Individual members of the mammalian N-acyl amino acids have been previously implicated in appetite, nociception, vasoregulation, and bone health ([@bib29]; [@bib30]; [@bib31]; [@bib41]; [@bib47]). We have recently identified a new role for certain N-acyl amino acids in stimulating oxidative metabolism via mitochondrial uncoupling ([@bib26]). These thermogenic N-acyl amino acids are characterized by medium-chain fatty acyl chains and neutral amino acid head groups, chemical features that are present in a subset of family members including N-acyl phenylalanines, N-acyl leucines, N-acyl glycines, and N-acyl serines ([@bib22]; [@bib24]). Consequently, administration of these N-acyl amino acids to mice rendered obese by feeding a high-fat diet increases energy expenditure, reduces adiposity, and improves glucose homeostasis.

Because of the potent effects of N-acyl amino acids on mitochondrial respiration and energy expenditure, the enzymes of N-acyl amino acid biosynthesis and degradation represent candidate pathways for regulating organismal energy homeostasis. To date, only a single mammalian enzyme called PM20D1 (peptidase M20 domain containing 1) has been identified as a physiologic regulator of endogenous N-acyl amino acid levels ([@bib26]; [@bib27]). PM20D1 is a classically secreted enzyme present in the circulation in both mice and humans ([@bib38]; [@bib44]). In vitro, recombinant PM20D1 functions as a bidirectional N-acyl amino acid synthase/hydrolase, catalyzing the biosynthesis of N-acyl amino acids from free fatty acids and free amino acids, as well as the reverse hydrolysis reaction. Overexpression of PM20D1 in mice, achieved by adeno-associated viral vectors, drives the biosynthesis of circulating N-acyl amino acids in vivo. These mice consequently have increased energy expenditure and reduced adiposity on high-fat diet. Conversely, global ablation of PM20D1 leads to a complex, bidirectional dysregulation of N-acyl amino acid levels and metabolic dysfunction characterized by glucose intolerance and decreased insulin sensitivity. Polymorphisms within and near the human *PM20D1* gene are linked to body mass index ([@bib5]; [@bib9]), providing powerful genetic evidence that PM20D1 may also regulate human obesity and metabolic disorders.

Beyond PM20D1, other mammalian enzymes are also likely to contribute to N-acyl amino acid metabolism, especially considering the large and structurally diverse nature of this lipid family ([@bib2]; [@bib6]; [@bib10]; [@bib46]). To date, the identity of these additional enzymes has remained unknown. Here we use PM20D1-KO tissues to molecularly characterize a second, PM20D1-independent N-acyl amino acid hydrolysis activity. We identify the responsible enzyme as fatty acid amide hydrolase (FAAH) and establish how PM20D1 and FAAH engage in extensive non-additive interactions in vivo to regulate the levels of N-acyl amino acids cooperatively. These data provide evidence for enzymatic division of labor as an enabling biochemical strategy for controlling the levels of a bioactive lipid family.

Results {#s2}
=======

Detection of a second, PM20D1-independent N-acyl amino acid hydrolysis activity {#s2-1}
-------------------------------------------------------------------------------

To characterize additional pathways of N-acyl amino acid metabolism in the absence of PM20D1, we analyzed tissue homogenates from wild-type and PM20D1-KO animals for a residual N-acyl amino acid hydrolysis activity. This assay was selected because of the high sensitivity and signal-to-noise ratio that it provides, which enables robust detection of any residual activities that might be present. Two different prototypical N-acyl amino acid substrates, N-arachidonoyl-phenylalanine (C20:4-Phe) and N-arachidonoyl-glycine (C20:4-Gly), were used as substrates. Following incubation with tissue lysates, the hydrolysis of these N-acyl amino acid substrates to free fatty acid product was quantified by liquid chromatography-mass spectrometry (LC-MS, [Figure 1a](#fig1){ref-type="fig"}). In wild-type mice, robust hydrolysis of C20:4-Phe was observed in eight of the ten tissues tested, with activities in the range of \~0.01 nmol/min/mg (lung) to 1.0 nmol/min/mg (liver). In PM20D1-KO tissues, the hydrolysis of C20:4-Phe was completely abolished (\>99% reduction in each tissue), establishing that PM20D1 is the only enzyme responsible for C20:4-Phe hydrolysis activity ([Figure 1b](#fig1){ref-type="fig"}). The presence of PM20D1 activity in tissue homogenates reflects potential interactions of PM20D1 with the extracellular matrix or with cell surfaces, as has previously been observed with lipoprotein lipase and other secreted enzymes ([@bib13]). By contrast, using C20:4-Gly as a substrate, both brain and liver from PM20D1-KO mice maintained a robust second hydrolysis activity ([Figure 1c](#fig1){ref-type="fig"}). The second PM20D1-independent activity accounted for 70% and 11% of the total C20:4-Gly hydrolysis in brain and liver, respectively. In absolute terms, the residual activity in PM20D1-KO liver was higher (0.10 nmol/min/mg) than that observed in the knockout brain tissue (0.03 nmol/min/mg). These data demonstrate the presence of a second, PM20D1-independent hydrolysis activity in brain and liver for C20:4-Gly. That this residual activity is only present for C20:4-Gly but not C20:4-Phe suggested that this second enzyme might exhibit selectivity for regulating subsets of lipid species within the N-acyl amino acid family.

![Detection of a residual N-acyl amino acid hydrolase activity in PM20D1-KO tissues.\
(**a**) Schematic of the enzymatic assay that monitors conversion of C20:4-Phe or C20:4-Gly into arachidonic acid. (**b, c**) C20:4-Phe (**b**) and C20:4-Gly (**c**) hydrolysis activities across the indicated wild-type (blue) or PM20D1-KO (orange) tissues. For (**b**) and (**c**), activity assays were conducted with 100 µM substrates and 100 µg tissue lysate in phosphate-buffered saline (PBS) for 1 hr at 37°C. Data are shown as means ± SEM, N = 3/group. All experiments were performed once, with N corresponding to biological replicates. \*, p\<0.05; \*\*, p\<0.01, \*\*\*, p\<0.001 for the indicated comparison.](elife-55211-fig1){#fig1}

Molecular identification of fatty acid amide hydrolase (FAAH) as the residual N-acyl amino acid hydrolase {#s2-2}
---------------------------------------------------------------------------------------------------------

Because liver homogenates exhibited the most robust PM20D1-independent hydrolysis activity, we initiated an effort to identify the enzyme responsible for this activity. We first began with a candidate approach. PM20D1 is one of five members of the mammalian M20 peptidase family, all of which exhibit peptide bond hydrolysis and condensation activity on a variety of small molecule substrates such as N-acetyl amino acids ([@bib37]), N-lactoyl amino acids ([@bib19]), and other dipeptides ([@bib23]; [@bib42]). However, it was not known whether any of the other mammalian M20 peptidases could also hydrolyze N-fatty acyl amino acids. We therefore recombinantly expressed each of the mammalian M20 peptidases by transient transfection into HEK293T cells. Cell lysates were harvested and total C20:4-Gly hydrolysis activity was determined by LC-MS. Only PM20D1-transfected cells exhibited robust conversion of C20:4-Gly to arachidonic acid ([Figure 2a](#fig2){ref-type="fig"}). These data therefore exclude any other mammalian M20 peptidases as a candidate enzyme for catalyzing the residual N-acyl amino acid hydrolysis activity in PM20D1-KO tissues.

![Identification of fatty acid amide hydrolase (FAAH) as the enzyme responsible for the PM20D1-independent N-acyl amino acid hydrolase activity.\
(**a, b**) C20:4-Gly hydrolysis activity of cell lysates transfected with the indicated mammalian M20 peptidase (**a**) or of the indicated liver homogenate fraction from PM20D1-KO animals (**b**). (**c, d**) Effect on the C20:4-Gly hydrolysis activity from PM20D1-KO liver membranes of the indicated inhibitors. Activity assays were conducted with 100 µM substrates and 100 µg tissue lysate in PBS for 1 hr at 37°C. For panel (**b**), membrane and soluble fractions of liver lysate were separated by centrifugation at 100,000 x g for 1 hr. For panel (**c**), inhibitors were pre-incubated at 1 mM for EDTA and 10 µM for all other compounds for 10 min before the start of the assay. Data are shown as means ± SEM, N = 3/group. All experiments were performed once, with N biological replicates. \*, p\<0.05; \*\*\*, p\<0.001 for the comparison versus DMSO or GFP control.](elife-55211-fig2){#fig2}

We next sought to characterize the enzymological properties of the residual hydrolysis activity from PM20D1-KO livers. Towards this end, livers from PM20D1-KO animals were separated by differential centrifugation at 100,000 x g. The C20:4-Gly hydrolysis activities from the membrane or soluble fraction were measured by LC-MS. Compared to the whole liver, the vast majority of the hydrolysis activity remained in the membrane fraction ([Figure 2b](#fig2){ref-type="fig"}). This observation suggested that the responsible enzyme contains a transmembrane domain or is otherwise tightly associated with cellular membranes. To determine which enzyme class may be contributing to this activity, we screened a variety of broad-spectrum enzyme inhibitors for their ability to block the C20:4-Gly hydrolysis activity. This panel included the divalent cation chelator EDTA (1 mM), HALT pan-protease inhibitor cocktail (1x), the pan-dipeptidyl peptidase inhibitor talabostat (10 µM), and the serine hydrolase inhibitor MAFP (methyl arachidonoyl fluorophosphonate, 10 µM). Remarkably, pre-treatment of PM20D1-KO liver membrane lysates with MAFP completely abolished the residual C20:4-Gly hydrolysis activity, whereas the other broad-spectrum enzyme inhibitors were entirely without effect ([Figure 2c](#fig2){ref-type="fig"}). These data strongly suggest that the residual hydrolysis activity is due to a serine hydrolase that is sensitive to MAFP inhibition.

The mammalian serine hydrolases are a large family of more than 250 enzymes ([@bib4]; [@bib28]). These hydrolases are characterized by a serine nucleophile that catalyzes hydrolytic reactions via a covalent acyl-enzyme intermediate. We focused on the subset of approximately 90 enzymes that have been previously described to be covalently inactivated by MAFP ([@bib3]). Of these, we excluded the dipeptidyl peptidases (DPPs) because the pan-DPP inhibitor talabostat did not recapitulate the activity of MAFP. From the remaining candidate serine hydrolases, we quickly focused on FAAH. FAAH is best recognized for its role in endocannabinoid signaling via hydrolysis of the cannabinoid receptor agonist anandamide (N-arachidonoyl-ethanolamine) ([@bib11]; [@bib12]). Nevertheless, three independent lines of evidence strongly suggest that FAAH may be responsible for the residual N-acyl amino acid hydrolysis activity. First, FAAH contains an N-terminal transmembrane domain and internal intramembrane region, consistent with the observation that the residual hydrolysis activity is localized to liver membranes rather than to the cytosolic fraction ([@bib33]). Second, FAAH has been shown to regulate several classes of bioactive fatty acid amides, including the N-acyl ethanolamines and N-acyl taurines, both of which share considerable structural similarity with N-acyl amino acids ([@bib16]; [@bib36]). Last, FAAH exhibits highest expression in brain and liver in mice, the two anatomical locations where we observe the highest residual N-acyl amino acid hydrolysis activity in PM20D1-KO mice ([@bib25]).

To determine whether FAAH could contribute to the residual hydrolysis activity in PM20D1-KO livers, we tested the effects of the potent and selective FAAH inhibitor PF-3845 ([@bib1]). This Pfizer compound has previously been shown to be highly selective and to inhibit only FAAH across multiple tissues following administration to mice. Pre-treatment of PM20D1-KO liver membrane lysates with PF-3845 (10 µM) completely blocked the residual hydrolysis activity exactly as was previously observed with MAFP ([Figure 2c](#fig2){ref-type="fig"}). By contrast, a distinct serine hydrolase inhibitor that does not inhibit FAAH (WWL70, 10 µM) had no effect on the residual C20:4-Gly hydrolysis activity. A dose--response curve established an EC50 of 290 nM for PF-3845, a concentration consistent with the previously reported potency of this compound towards FAAH ([Figure 2d](#fig2){ref-type="fig"}). Taken together, these data establish FAAH as the enzyme responsible for the residual N-acyl amino acid hydrolysis activity in PM20D1-KO tissues.

PM20D1 and FAAH exhibit overlapping but distinct substrate specificity in vitro {#s2-3}
-------------------------------------------------------------------------------

We next performed alignments of the primary amino acid sequences of mouse PM20D1 and mouse FAAH ([Figure 3a](#fig3){ref-type="fig"}). As additional comparisons, we also included QRSL1 (glutamyl-tRNA amidotransferase subunit A, mitochondrial), which is the closest murine homolog to FAAH (17% identity), as well as the other four members of the murine M20 peptidase family. PM20D1 was most closely related to ACY1 (24% identity) and shared little identity with FAAH (11%). Our clustering also revealed a closer relationship of PM20D2 with both FAAH and QRSL1 than with the other M20 peptidase family members ([Figure 3a](#fig3){ref-type="fig"}).

![N-acyl amino acid hydrolase and synthase substrate scope in vitro for FAAH and PM20D1.\
(**a**) Phylogenetic alignment of the five murine M20 peptidases with mouse FAAH and a FAAH-related enzyme, QRSL1. Orange, M20 peptidases; gray, FAAH-related sequences. (**b**) Anti-flag western blot for cell lysates (left) and conditioned media (right) transfected with the indicated plasmids. (**c--f**) N-acyl amino acid hydrolysis and synthase activities of FAAH- and mock-transfected cell lysates (**b, c**) or PM20D1-transfected and mock-transfected conditioned media (**d, e**). Activity assays were conducted with 100 µM substrates and 100 µg protein in PBS for 1 hr at 37°C. Data are shown as means ± SEM, N = 3/group. All experiments were performed once, with N biological replicates. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001 for the indicated comparison.](elife-55211-fig3){#fig3}

To determine whether N-acyl amino acids are direct FAAH substrates in vitro, we generated recombinant FAAH protein by transient transfection of a C-terminal flag-tagged FAAH construct into HEK293T cells. As a direct comparison, recombinant PM20D1 was generated in parallel. As expected, FAAH was localized entirely intracellularly, consistent with its previously described localization as an ER-associated transmembrane enzyme, whereas PM20D1 protein was largely found in the conditioned media, consistent with its known annotation as a classically secreted enzyme ([Figure 3b](#fig3){ref-type="fig"}). Using these transfected lysates (for FAAH) and conditioned media (for PM20D1), hydrolysis activity across a diverse panel of 14 N-acyl amino acid substrates was determined by LC-MS. These 14 substrates varied by both amino acid head group and fatty acid chain. FAAH-transfected cells showed robust hydrolysis activity for four N-acyl amino acids tested: C18:1-Gly, C18:1-Ser, C20:4-Gly, and C20:4-Ser ([Figure 3c](#fig3){ref-type="fig"}). A strong preference was observed for C20:4-Ser over the other three N-acyl amino acid substrates (\~1.5 nmol/min/mg for FAAH hydrolysis of C20:4-Ser versus 0.05--0.15 nmol/min/mg for any of the other substrates), at least under these in vitro conditions. In the N-acyl amino acid synthase direction, FAAH also catalyzed the condensation of arachidonic acid with Gly and Ser, but not Phe ([Figure 3d](#fig3){ref-type="fig"}). By contrast, robust hydrolysis activity was observed for PM20D1 across nearly all members of this N-acyl amino acid substrate panel over mock-transfected background ([Figure 3e](#fig3){ref-type="fig"}). PM20D1 also efficiently catalyzed the condensation of arachidonic acid with all three Gly, Ser, and Phe amino acids ([Figure 3f](#fig3){ref-type="fig"}).

To better understand FAAH-mediated N-arachidonoyl glycine hydrolysis activity in the context of its previously described amidase activities, we directly compared the hydrolytic activity of transfected FAAH on C20:4-Gly, anandamide (C20:4-NAE), and N-arachidonoyl-taurine (C20:4-NAT). As expected, FAAH showed robust hydrolysis activity with anandamide as a substrate (0.5 nmol/min/mg) and lower but similar activities with C20:4-NAT and C20:4-Gly (0.04 and 0.02 nmol/min/mg, respectively, [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). Conversely, PM20D1 exhibited robust hydrolysis activity only on C20:4-Gly (0.6 nmol/min/mg) and was unable to hydrolyze either anandamide or C20:4-NAT ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). We also determined that C20:4-NAT was not a direct inhibitor for PM20D1 ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Taken together, these data establish that recombinant FAAH is an N-acyl amino acid synthase/hydrolase in vitro. Our findings also underscore the PM20D1--FAAH pair as an example of convergence in enzymatic activity despite divergence in primary sequence.

N-acyl amino acid metabolism in mice with selective FAAH blockade {#s2-4}
-----------------------------------------------------------------

Although FAAH is a dominant regulator of several classes of bioactive fatty acid amides in vivo ([@bib12]; [@bib16]; [@bib17]; [@bib36]), the physiologic role of FAAH in regulating N-acyl amino acids has not been systematically explored. Furthermore, considering the intracellular localization of FAAH compared with PM20D1, whether FAAH has a broad role or whether it regulates specific pools of N-acyl amino acids remains unknown. To determine the relevance of the FAAH/N-acyl amino acid pathway in vivo, we measured endogenous N-acyl amino acid levels following blockade of FAAH in mice. Because both genetic and pharmacological reagents for selective FAAH blockade were available, we performed three independent comparisons: global FAAH-KO versus FAAH-WT mice, a single administration of PF-3845 versus vehicle (10 mg/kg intraperitoneally, 'acute'), or a three-day administration of PF-3845 versus vehicle (10 mg/kg intraperitoneally once per day, 'chronic'). These three comparisons were selected because they had previously been validated to cause dramatic accumulation of other physiologic FAAH substrates in vivo ([@bib25]).

Liver and blood were harvested and N-acyl amino acids were extracted by homogenization in acetonitrile/methanol. We developed a targeted liquid chromatography-triple quadrupole mass spectrometry (LC-QQQ) method to measure a panel of oleoyl- or arachidonoyl-containing N-acyl amino acids, reasoning that such a set would broadly capture a diverse and representative panel of this lipid family. In these experiments, we were able to detect 26 and 14 N-acyl amino acid species in liver and blood, respectively ([Figure 4a](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"} and [2](#fig4sdata2){ref-type="supplementary-material"}). In the liver, distinct bidirectional changes in N-acyl amino acids were observed in each of the three perturbations. Those changes that were statistically significant across all three conditions of FAAH blockade were elevations in C20:4-Glu (by 2.1-fold) and decreases in C20:4-Gly (by 70%). In other cases, certain N-acyl amino acids changes were only observed in either the genetic (e.g., increased C20:4-Leu/Ile) or pharmacological (e.g., increased C18:1-Glu) model. In the blood, no N-acyl amino acids were significantly changed over controls across all three experiments ([Figure 4b](#fig4){ref-type="fig"}). We confirmed that PM20D1 activity is not altered in FAAH-KO plasma ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). By abundance, hepatic N-acyl amino acids levels were similar to N-acyl ethanolamine and N-acyl taurines in wild-type mice ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"} and [2](#fig4sdata2){ref-type="supplementary-material"}). Taken together, these data demonstrate that FAAH is a bidirectional regulator of a subset of intracellular, but not extracellular, N-acyl amino acids.

![Changes in N-acyl amino acids upon selective blockade of FAAH in vivo.\
(**a, b**) Fold change of the indicated N-acyl amino acids compared to the control for each of the indicated comparisons from liver (**a**) or blood (**b**). For drug treatment, PF-3845 was administered intraperitoneally at 10 mg/kg once (acute) or for three consecutive days (chronic). Tissues were harvested 3 hr after the final dose. No bars are shown for N-acyl amino acids that were below the limit of detection. Data are shown as means ± SEM, N = 4--5 mice/group for each of the indicated comparisons. All experiments were performed once, with N biological replicates. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001 by ANOVA with Dunnett's multiple comparisons test versus control animals.\
Figure 4---source data 1.Absolute quantitation of N-acyl amino acids in liver and plasma following FAAH blockade.\
Figure 4---source data 2.Absolute quantitation of N-acyl ethanolamines and N-acyl taurines in wild-type mouse liver.](elife-55211-fig4){#fig4}

Cooperative regulation of N-acyl amino acids by PM20D1 and FAAH in vivo {#s2-5}
-----------------------------------------------------------------------

Our data establish that at least two enzymes, PM20D1 and FAAH, contribute to the regulation of endogenous N-acyl amino acid levels. Individual blockade of PM20D1 or FAAH resulted in bidirectional dysregulation of N-acyl amino acids. We therefore considered the possibility that dual inhibition of both PM20D1 and FAAH would result in a complete ablation of N-acyl amino acid synthase/hydrolase activities, and in concomitant global elevations or global depletions of endogenous N-acyl amino acid levels. To test this hypothesis, we used global PM20D1-KO animals in combination with a FAAH inhibitor to block both PM20D1 and FAAH simultaneously. PM20D1-KO animals were chronically treated with PF-3845 (10 mg/kg intraperitoneally once per day for three days). As controls, PM20D1-KO or PM20D1-WT littermates were administered vehicle control (saline) in parallel. First, we measured liver N-acyl amino acid hydrolysis activity from each of the three groups of mice. As we described previously, livers from vehicle-treated PM20D1-KO mice exhibited a residual C20:4-Gly hydrolysis activity when compared to livers from PM20D1-WT mice. Following PF-3845 treatment in PM20D1-KO mice, the residual hepatic C20:4-Gly hydrolysis activity was entirely abolished ([Figure 5a](#fig5){ref-type="fig"}). These data establish that PM20D1 and FAAH are the only two C20:4-Gly hydrolysis activities in liver, at least under the assay conditions used here, and further validate our previous in vitro studies ([Figure 2c,d](#fig2){ref-type="fig"}).

![Cooperative interactions between PM20D1 and FAAH regulate endogenous N-acyl amino acid levels.\
(**a**) C20:4-Gly hydrolysis activity in livers from PM20D1-WT, PM20D1-KO, or PM20D1-KO treated with PF-3845. (**b, c**) Relative fold change of the indicated N-acyl amino acids in PM20D1-KO mice or in PM20D1-KO mice treated with PF-3845 versus wild-type mice in liver (**b**) or blood (**c**). For drug treatment, PF-3845 was administered intraperitoneally at 10 mg/kg for three consecutive days and tissues were harvested 3 hr after the final dose. No bars are shown for N-acyl amino acids that were below the limit of detection. Data are shown as means ± SEM, N = 4--5 mice/group for each of the indicated comparisons. All experiments were performed once, with N biological replicates. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001 in color are versus PM20D1-WT levels, whereas those in black are for the indicated comparison by ANOVA with Tukey's multiple comparison test.\
Figure 5---source data 1.Absolute quantitation of N-acyl amino acids in liver and plasma following PM20D1 or dual PM20D1/FAAH blockade.](elife-55211-fig5){#fig5}

Next, we measured endogenous N-acyl amino acid levels in both liver and blood. Under basal conditions, PM20D1-KO mice exhibit bidirectional dysregulation of several N-acyl amino acids compared to PM20D1-WT mice ([Figure 5b](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Surprisingly, complete ablation of N-acyl amino acid synthase/hydrolase activities did not uniformly change N-acyl amino acids in a positive or negative direction. Instead, dual inhibition of PM20D1 and FAAH uncovered a remarkable cooperativity of these two enzymatic pathways in the regulation of N-acyl amino acids. In general, individual regulation by PM20D1 or FAAH were not predictive of those N-acyl amino acid species that were regulated by both enzymatic pathways together or even the directionality of change. For instance, hepatic N-acyl serines were largely unaltered by individual blockade of either FAAH or PM20D1 alone ([Figure 4a](#fig4){ref-type="fig"} and [Figure 5b](#fig5){ref-type="fig"}). Following dual blockade of both enzymes, C18:1-Ser and C20:4-Ser were dramatically accumulated by 13-fold and 26-fold, respectively ([Figure 5b](#fig5){ref-type="fig"}). In other cases, dual blockade resulted in changes to N-acyl amino acids in the opposite direction compared to individual blockade alone. For instance, C18:1-Gly was reduced in PM20D1-KO livers and unaltered by FAAH blockade, but nevertheless accumulated to 8-fold over controls when both enzymes were inhibited. In the blood, similar cooperative interactions could also be observed ([Figure 5c](#fig5){ref-type="fig"}). In some cases, the directionality of the N-acyl amino acid changes was concordant in blood and liver (e.g., N-acyl glycines and N-acyl leucines), whereas in other cases (e.g., C18:1-Met), the intracellular pools accumulated with a concomitant decrease in extracellular levels. These data establish that PM20D1 and FAAH engage in non-additive crosstalk in vivo to regulate intracellular and circulating levels of N-acyl amino acids .

Discussion {#s3}
==========

The N-acyl amino acids are a diverse bioactive lipid family. Using PM20D1-KO tissues as a discovery tool, we establish FAAH as a second intracellular mammalian N-acyl amino acid synthase/hydrolase. In vitro, FAAH catalyzes the bidirectional synthesis and hydrolysis of a subset of N-acyl amino acids that have a narrower substrate specificity than PM20D1. Genetic ablation or pharmacological inhibition of FAAH in vivo established that this enzyme is also a physiological regulator of intracellular but not of extracellular N-acyl amino acids. Our data uncover the PM20D1--FAAH pair as an example of enzymatic convergence, despite largely unrelated primary amino acid sequences. More generally, these findings underscore enzymatic and spatial division of labor as a mechanism for the control of subsets of a diverse thermogenic lipid family.

The identification of two mammalian N-acyl amino acid synthase/hydrolase enzymes, one localized extracellularly and one intracellularly, raises important questions about the similarities and differences between the N-acyl amino acids within each of these localizations and about crosstalk between the intracellular and extracellular pools of N-acyl amino acids. What factors determine the compartmentalization of N-acyl amino acids? What are the mechanisms by which these lipids are imported into or exported out of cells? What functional differences are there between these two pools of N-acyl amino acids? One possibility is that certain N-acyl amino acid bioactivities require interactions within the cell (e.g., binding to mitochondria to stimulate respiratory uncoupling) whereas others involve extracellular interactions (e.g., engaging cell surface receptors), suggesting that certain compartmentalized pools of N-acyl amino acids might be more relevant for specific bioactivities. Identifying specific transporters for N-acyl amino acids may help to clarify the relative contribution of the intracellular versus extracellular pools of these lipids. The many examples of intra- and inter-cellular transport of sterols ([@bib35]), fatty acids ([@bib34]), and phospholipids ([@bib18]) provide a fertile starting point for discovering analogous pathways for the transport and compartmentalization of N-acyl amino acids.

FAAH has also been implicated in diverse physiologic conditions in mice and humans. Pharmacological or genetic blockade of FAAH has been shown to regulate pain and inflammation ([@bib1]; [@bib12]), obesity and metabolic homeostasis ([@bib8]; [@bib43]), and anxiety and depression ([@bib15]; [@bib21]), amongst many others. Polymorphisms in the *FAAH* gene have also provided human genetic evidence for these disease associations ([@bib39]; [@bib40]). These phenotypes are classically associated with anandamide elevation and activation of the cannabinoid receptors upon FAAH inhibition or genetic deletion. However, beyond the endocannabinoid system, FAAH also regulates several other classes of bioactive lipids including other N-acyl ethanolamines, N-acyl taurines, and now, N-acyl amino acids. We propose that FAAH-regulated N-acyl amino acids may also contribute to some of these observed phenotypes. Projecting forward, critical tests of the FAAH/N-acyl amino acid contribution without confounding contributions from other FAAH-regulated lipids will require the identification of selective FAAH point mutants that only catalyze the synthesis or hydrolysis of specific species of N-acyl amino acids, but not other fatty acid amide substrates.

Our data reveal that complete ablation of all C20:4-Gly synthase/hydrolase activities via dual blockade of both PM20D1 and FAAH was not sufficient to elevate or deplete all endogenous N-acyl amino acids globally. Instead, we observed extensive and non-additive interactions between these two enzymatic pathways in the regulation of specific subsets of N-acyl amino acids. In general, these non-additive interactions could not be predicted by in vitro substrate specificity or even individual N-acyl amino acid regulation. To the best of our knowledge, this type of cooperativity has not been previously described for any biochemical pathway. Quantitative flux analysis for the various amino acid, fatty acid, and N-acyl amino acid components will be required to understand how these metabolic fluxes are re-wired upon blockade of each enzyme individually or together.

Last, our findings suggest that additional biochemical pathways beyond PM20D1 and FAAH contribute to regulating the endogenous levels of this lipid family. Potential candidate pathways include additional amidase enzymes on other N-acyl amino acid substrates, enzymes that catalyze the conjugation of fatty acid CoAs with amino acids, or non-mammalian sources ([@bib7]; [@bib10]; [@bib20]; [@bib45]). Molecular identification of these additional pathways of N-acyl amino acid metabolism will ultimately enable the dissection and therapeutic manipulation of more specific subsets of this diverse bioactive lipid family in organismal physiology.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                       Source or\                                                                 Identifiers   Additional\
  (species) or\                                                             reference                                                                                information
  resource                                                                                                                                                           
  --------------------------------------- --------------------------------- -------------------------------------------------------------------------- ------------- -------------
  Mouse line (*Mus musculus*)             PM20D1-KO                         [@bib27]\                                                                                
                                                                            (PMID:[29967167](https://www.ncbi.nlm.nih.gov/pubmed/29967167))                          

  Mouse line (*M. musculus*)              C57BL/6J                          Jackson Labs                                                               000664        

  Transfected construct\                  PM20D1-flag                       Addgene                                                                    84566         
  (*M. musculus*)                                                                                                                                                    

  Transfected construct (*M. musculus*)   FAAH-flag                         Origene                                                                    MR209084      

  Transfected construct (*M. musculus*)   ACY1-flag                         Origene                                                                    MR206415      

  Transfected construct (*M. musculus*)   CNDP1-flag                        Origene                                                                    MR219018      

  Transfected\                            CNDP2-flag                        Origene                                                                    MR207616      
  construct (*M. musculus*)                                                                                                                                          

  Transfected construct (*M. musculus*)   PM20D2-flag                       Origene                                                                    MR222068      

  Cell line (*Homo sapiens*)              HEK293T                           ATCC                                                                       CRL-3216      

  Antibody                                Anti-flag M2, mouse monoclonal    Sigma                                                                      F1804         (1:1000)

  Antibody                                Anti-tubulin, rabbit polyclonal   Abcam                                                                      Ab6046        (1:1000)

  Chemical compound                       PF-3845                           Selleckchem                                                                S2666         

  Chemical compound                       C20:4-Gly                         Cayman                                                                     90051         

  Chemical compound                       C20:4-Ser                         Cayman                                                                     10005455      

  Chemical compound                       C20:4-Phe                         Abcam                                                                      Ab141612      

  Chemical\                               Arachidonic acid                  Sigma-Aldrich                                                              10931         
  compound                                                                                                                                                           

  Chemical compound                       WWL70                             Sigma-Aldrich                                                              SML1641       

  Chemical compound                       Talabostat                        R and D                                                                    3719          

  Chemical\                               MAFP                              Fisher Scientific                                                          14-21-5       
  compound                                                                                                                                                           

  Chemical\                               C20:4-NAT                         Cayman                                                                     10005537      
  compound                                                                                                                                                           

  Chemical compound                       Anandamide                        Sigma-Aldrich                                                              A0580         

  Chemical compound                       C16:0-Phe                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:0-Phe                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical\                               C20:0-Phe                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 
  compound                                                                                                                                                           

  Chemical compound                       C22:6-Phe                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Asn                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Gly                         Cayman                                                                     90269         

  Chemical compound                       C18:1-Lys                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Met                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Ser                         Cayman                                                                     13058         

  Chemical compound                       C18:1-Trp                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Tyr                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 

  Chemical compound                       C18:1-Gln                         [@bib24] (PMID:[29533650](https://www.ncbi.nlm.nih.gov/pubmed/29533650))                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

General animal information {#s4-1}
--------------------------

Animal experiments were performed according to procedures approved by the Stanford University IACUC. Mice were maintained in 12 hr light-dark cycles at 22°C and fed a standard irradiated rodent chow diet. All experiments on wild-type mice were performed with male C57BL/6J mice purchased from Jackson Laboratories (stock number 000664). Global *Pm20d1* knockout mice were obtained from Bruce M. Spiegelman (Dana-Farber Cancer Institute) and are available from Jackson Laboratories (stock number 032193). PF-3845 was administered to mice in a solution of 18:1:1 saline:kolliphor EL:DMSO in a volume of 200 µl/mouse (intraperitoneally).

Materials {#s4-2}
---------

N-arachidonoyl glycine, N-arachidonoyl serine, and N-arachidonoyl-taurine were purchased from Cayman. N-arachidonoyl phenylalanine was purchased from Abcam. Arachidonic acid, anandamide, and WWL70 were purchased from Sigma-Aldrich. PF-3845 was purchased from Selleckchem. MAFP and EDTA were purchased from Fisher. Talabostat was purchased from R and D. Non-commercially available N-acyl amino acids were synthesized as previously described ([@bib24]; [@bib26]). Plasmids were obtained from the following sources: mouse PM20D1-flag (Addgene 132682), mouse FAAH-flag (Origene MR209084), mouse ACY1-flag (Origene MR206415), mouse CNDP1-flag (Origene MR219018), mouse CNDP2-flag (Origene MR207616), and mouse PM20D2-flag (MR222068).

Statistics, sample size estimation, and replicates {#s4-3}
--------------------------------------------------

All statistical comparisons were performed using Student's t-test or ANOVA with Tukey or Dunnett's multiple comparison test. No explicit power analysis was used to determine sample sizes. Sample sizes were determined on the basis of previous literature for biochemical or animal studies. All experiments were performed once, with N corresponding to biological replicates. Outliers were not removed from analyses. The experimentalist was not blinded to sample or treatment conditions.

Cell culture {#s4-4}
------------

HEK293T cells were obtained from ATCC (CRL-3216) and cultured in DMEM with L-glutamine, 4.5 g/L glucose and sodium pyruvate (Corning 10013CV) supplemented with 10% FBS (Corning 35010CV). Cells were incubated at 37°C in 5% CO~2~ for growth and tranfections. All cell lines were authenticated by DNA fingerprint STR analysis by ATCC. Mycoplasma was not tested. Authentication of cell lines beyond ATCC was not completed due to laboratory disruptions by COVID-19.

Production of recombinant enzymes {#s4-5}
---------------------------------

Plasmids were transiently transfected into HEK293T cells using PolyFect (Qiagen) according to the manufacturer's instructions. The medium was changed to serum-free DMEM one day post-transfection. After an additional 24 hr, the medium was collected and the cells were harvested by scraping.

Molecular studies {#s4-6}
-----------------

Western blotting was performed according to standard methods. The following antibodies were used: anti-flag M2 antibody (Sigma F1804, diluted 1:10,000), and tubulin (Abcam ab6046, diluted 1:10,000).

Enzyme activity assays in vitro {#s4-7}
-------------------------------

Plasma was collected from mice and used directly for the activity assays. Tissues were homogenized using a Benchmark BeadBlaster Homogenizer in ice-cold PBS, centrifuged to remove debris (5 min at 1000 x g), and the supernatant was collected and used for activity assays. For assays using liver membranes, total liver homogenates were transferred into ultracentrifuge inserts and spun at 100,000 x g on a Beckman Centrifuge I8-70M for 1 hr at 4°C. In vitro enzymatic reactions were conducted in glass vials and initiated by the addition of 100 µg protein. Final reaction conditions for the hydrolase reactions were 100 µM substrate (C20:4-Gly or C20:4-Phe) and 100 µg protein in 100 µl PBS, and for the synthase reactions were 1 mM Phe, 1 mM oleic acid, and 100 µg protein in 100 µl PBS. After 1 hr at 37°C, reactions were quenched with 400 µl 2:1 v/v acetonitrile:methanol and vortexed. Reaction vials were centrifuged at 2000 x g to remove debris, and the supernatant was collected and analyzed by LC-MS as described below. For inhibitor assays, tissue lysates were treated with the indicated inhibitors for 10 min at room temperature before the introduction of the indicated substrates.

Extraction of N-acyl amino acids from blood and tissues {#s4-8}
-------------------------------------------------------

Frozen plasma (30 μl) were extracted in 160 μl of 1:1 v/v acetonitrile:methanol. Liver tissues were extracted in 500 μl 2:2:1 v/v/v acetonitrile:methanol:water on a BeadBlaster homogenizer for 1 min. Extracts were centrifuged (10 min, 5000 x g) to remove debris. The supernatant was isolated and centrifuged again (10 min, 5000 x g). Finally, the twice-clarified supernatant was transferred to a mass spectrometry vial and analyzed by LC-MS as described below.

Measurements of N-acyl amino acids in vivo and enzyme activities in vitro by LC-MS {#s4-9}
----------------------------------------------------------------------------------

Mass spectrometry analysis was performed with an electrospray ionization (ESI) source on an Agilent 6470 Triple Quadrupole (QQQ). For separation of metabolites, normal-phase chromatography was performed with a Luna 5 µm C5 100 Å LC column (Phenomenex 00B-4043-E0). The mobile phases were as follows: Buffer A, 95:5 water/methanol; Buffer B, 60:35:5 isopropanol/methanol/water with 0.1% ammonium hydroxide in both Buffer A and B for negative ionization mode. For AJS ESI ion source parameters, the drying gas temperature was set to 250°C with a flow rate of 12 l/min, and the nebulizer pressure was 25 psi. The sheath gas temperature was set to 300°C with a flow rate of 12 l/min. The capillary voltage was set to 2500 V and the fragmentor voltage was set to 135 V. For the measurement of in vitro enzyme activity assays, the flow rate for each run started at 95% A/5% B for 3 min at 0.6 ml/min, followed by a gradient starting at 95% A/5% B changing linearly to 5% A/95% B over the course of 3 min at 0.6 ml/min, followed by 5% A/95% B for 1.5 min at 0.6 ml/min. For the measurement of metabolites from blood and liver in vivo, the flow rate for each run started at 95% A/5% B for 1 min at 0.6 ml/min, followed by a gradient starting at 95% A/5% B changing linearly to 5% A/95% B over the course of 10 min at 0.6 ml/min, followed by 5% A/95% B for 3 min at 0.6 ml/min, and back to 95% A/5% B over 1 min at 0.6 ml/min.

The QQQ acquisition parameters were as follows. For in vitro assays, the mass range was set from 100 to 500 m/z. For measurement of endogenous N-acyl amino acids, metabolites were detected by the SRM of the transition from precursor to product ions (corresponding to the amino acid fragment) at collision energy 20. The following table includes the list of transitions used. N-acyl taurines and N-acyl ethanolamines were measured as described previously ([@bib25]).

Compound namePrecursor ionProduct ionDwellFragmentorCollision energyCell accelerator voltagePolarityC18:1-Trp467.3203.150135205NegativeC20:4-Tyr466.3180.150135205NegativeC20:4-Arg459.4173.150135205NegativeC20:4-Phe450.3164.150135205NegativeC18:1-Tyr444.3180.150135205NegativeC20:4-His440.3154.150135205NegativeC18:1-Arg437.4173.150135205NegativeC20:4-Met434.314850135205NegativeC20:4-Glu432.3146.150135205NegativeC20:4-Gln/Lys431.3145.150135205NegativeC18:1-Phe428.3164.150135205NegativeC18:1-His418.3154.150135205NegativeC20:4-Asp418.313250135205NegativeC20:4-Asn417.3131.150135205NegativeC20:4-Leu/Ile416.4130.150135205NegativeC18:1-Met412.314850135205NegativeC18:1-Glu410.3146.150135205NegativeC18:1-Gln/lys409.3145.150135205NegativeC20:4-Cys406.312050135205NegativeC20:4-Thr404.3118.150135205NegativeC20:4-Val402.3116.150135205NegativeC20:4-Pro400.3114.150135205NegativeC18:1-Asp396.313250135205NegativeC18:1-Asn395.3131.150135205NegativeC18:1-Leu/Ile394.4130.150135205NegativeC20:4-Ser390.310450135205NegativeC15-Phe388.3164.150135205NegativeC18:1-Cys384.312050135205NegativeC18:1-Thr382.3118.150135205NegativeC18:1-Val380.3116.150135205NegativeC18:1-Pro378.3114.150135205NegativeC20:4-Ala374.38850135205NegativeC18:1-Ser368.310450135205NegativeC20:4-Gly360.37450135205NegativeC18:1-Ala352.38850135205NegativeC18:1-Gly338.37450135205NegativeC20:4-Trp489.3203.150135205Negative
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

N-acyl amino acids are an emerging family of lipid signaling molecules composed of a fatty acid chain conjugated to amino acids. These bioactive lipids have potentially far-reaching impacts on metabolism, yet their regulation is still not fully understood. This paper identifies fatty acid amide hydrolase (FAAH) as an enzyme that acts in concert with a previously identified enzyme PM20D1 to regulate levels of the N-acyl amino acids. Identification of this additional pathway will enable further dissection of the metabolic roles of this bioactive lipid family.

**Decision letter after peer review:**

Thank you for submitting your article \"Cooperative enzymatic control of N-acyl amino acids by PM20D1 and FAAH\" for consideration by *eLife*. Your article has been reviewed by Michael Marletta as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Matthew Paul Gillum (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Kim et al. report the identification of fatty acid amide hydrolase (FAAH) as an enzyme that regulates levels of N-acyl amino acids together with previously identified PM20D1. The N-acyl amino acids are an emerging family of lipid signals with potentially far-reaching impacts on metabolism, and this work demonstrates how FAAH and PM20D1 act in concert to regulate the levels of this signal. All three reviewers were supportive and agreed that this work was an interesting contribution to this field. A few concerns were raised that the authors should be able to address with additional data and/or clarifying explanations.

Essential revisions:

1\) A major question is whether FAAH\'s primary substrate in the liver N-acyl taurines could be indirectly causing the effects observed in vivo. First, it would be good to know the concentrations of N-acyl amino acids compare to the NATs (or NAEs in the brain). Most of the data in the manuscript are reported as a fold-change, but it would be good to know the relative levels of FAAH substrates in vivo to know if the N-acyl amino acids constitute a significant substrate source for FAAH. Second, a likely explanation is that the absence of FAAH regulates some N-acyl amino acids because these are direct FAAH substrates. However, another model that might lead to similar data is that the absence of FAAH results in high NAT levels that can regulate PM20D1 leading to increased levels of some N-acyl amino acids. What are the effects on PM20D1 expression in FAAH-KO mice? If there are effects, it would be good to check that NATs are not secondary PM20D1 substrates or inhibitors that could influence the activity of this enzyme. The result would be interesting regardless since it could reveal additional crosstalk between the systems. In vitro assays with tissue lysates and pure enzymes +/- NATs should suffice.

2\) As a related point to \#1, it would be useful to discuss (or measure) the rate of FAAH-mediated N-acyl taurine hydrolysis compared to that for N-acyl amino acid hydrolysis, to put this new FAAH activity in context.

3\) The activity of PM20D1 appears high in tissue (i.e. liver and kidney), though it is discussed as a secreted enzyme? Can the authors clarify this?

10.7554/eLife.55211.sa2

Author response

> Essential revisions:
>
> 1\) A major question is whether FAAH\'s primary substrate in the liver N-acyl taurines could be indirectly causing the effects observed in vivo. First, it would be good to know the concentrations of N-acyl amino acids compare to the NATs (or NAEs in the brain). Most of the data in the manuscript are reported as a fold-change, but it would be good to know the relative levels of FAAH substrates in vivo to know if the N-acyl amino acids constitute a significant substrate source for FAAH.

We thank the reviewers for these suggestions. We have now provided absolute quantitation of hepatic N-acyl amino acids, N-acyl ethanolamines, and N-acyl taurines in three new source data files (Figure 4---source data 1, Figure 4---source data 2, and Figure 5---source data 1). These data show that N-acyl amino acids are in the range of 10-800 pmol/g, depending on the precise species and experiment. For comparison, N-acyl taurines were on average \~400 pmol/g as were N-acyl ethanolamines (average \~100 pmol/g). In the main text, we have now added the following sentence to subsection "N-acyl amino acid metabolism in mice with selective FAAH blockade": "By abundance, hepatic N-acyl amino acids levels were similar to N-acyl ethanolamine and N-acyl taurines in wild-type mice (Figure 4---source data 1 and Figure 4---source data 2)."

> Second, a likely explanation is that the absence of FAAH regulates some N-acyl amino acids because these are direct FAAH substrates. However, another model that might lead to similar data is that the absence of FAAH results in high NAT levels that can regulate PM20D1 leading to increased levels of some N-acyl amino acids. What are the effects on PM20D1 expression in FAAH-KO mice? If there are effects, it would be good to check that NATs are not secondary PM20D1 substrates or inhibitors that could influence the activity of this enzyme. The result would be interesting regardless since it could reveal additional crosstalk between the systems. In vitro assays with tissue lysates and pure enzymes +/- NATs should suffice.

To directly address this question, we have measured PM20D1 activity in plasma from WT and FAAH-KO mice. As shown in Figure 4---figure supplement 1, we did not observe any differences in PM20D1 activity between these two genotypes, suggesting that FAAH deficiency does not indirectly alter PM20D1 levels. We have added the following sentence to subsection "N-acyl amino acid metabolism in mice with selective FAAH blockade": "We confirmed that PM20D1 activity is not altered in FAAH-KO plasma (Figure 4---figure supplement 1)."

We have now also determined that NATs are not secondary PM20D1 substrates or inhibitors by direct in vitro enzymatic assay. As shown in Figure 3---figure supplement 1, PM20D1 hydrolyzes only C20:4-Gly, but not C20:4-NAT or anandamide. Furthermore, the presence of C20:4-NAT does not inhibit PM20D1 activity, as measured by C20:4-Gly hydrolysis. To reflect these new data, we have added the following sentences in subsection "PM20D1 and FAAH exhibit overlapping but distinct substrate specificity in vitro": "Conversely, PM20D1 exhibited robust hydrolysis activity only on C20:4-Gly (0.6 nmol/min/mg) and was unable to hydrolyze either anandamide or C20:4-NAT (Figure 3---figure supplement 1A). We also determined that C20:4-NAT was not a directly inhibitor for PM20D1 (Figure 3---figure supplement 1B)."

> 2\) As a related point to \#1, it would be useful to discuss (or measure) the rate of FAAH-mediated N-acyl taurine hydrolysis compared to that for N-acyl amino acid hydrolysis, to put this new FAAH activity in context.

We have now compared FAAH amidase activity on anandamide, C20:4-NAT, and C20:4-Gly side by side and included these data in Figure 3---figure supplement 1. Our data show that FAAH exhibits most robust activity on anandamide and lower, but still comparable activities on C20:4-NAT and C20:4-Gly. We have now discussed these new results in subsection "PM20D1 and FAAH exhibit overlapping but distinct substrate specificity in vitro": "To better understand FAAH-mediated N-arachidonoyl glycine hydrolysis activity in the context of its previously described amidase activities, we directly compared the hydrolytic activity of transfected FAAH on C20:4-Gly, anandamide (C20:4-NAE), and N-arachidonoyl-taurine (C20:4-NAT). As expected, FAAH showed robust hydrolysis activity with anandamide as a substrate (0.5 nmol/min/mg) and lower, but similar activities with C20:4-NAT and C20:4-Gly (0.04 and 0.02 nmol/min/mg, respectively, Figure 3---figure supplement 1A)."

> 3\) The activity of PM20D1 appears high in tissue (i.e. liver and kidney), though it is discussed as a secreted enzyme? Can the authors clarify this?

We agree with the reviewers that this point of confusion requires clarification. Many other enzymes secreted into the blood can also be directly detected in tissue homogenates, with one of the best examples being lipoprotein lipase (LPL). LPL activity in adipose and muscle tissues likely reflects the association of this enzyme to the endothelial cell surfaces and extracellular matrix within the tissues. To clarify our finding of PM20D1 activity in tissue lysates, we have added the following sentence to subsection "Detection of a second, PM20D1-independent N-acyl amino acid hydrolysis activity": "The presence of PM20D1 activity in tissue homogenates reflects potential interactions of PM20D1 with the extracellular matrix or with cell surfaces, as has previously been observed with lipoprotein lipase and other secreted enzymes (Cryer, 1981)."
